Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse for at evaluere effektiviteten og sikkerheden af ​​CIN-102 (Deudomperidon) hos voksne med diabetisk gastroparese

3. november 2026 opdateret af: CinDome Pharma, Inc.

En randomiseret, dobbeltblind, placebokontrolleret, multicenterundersøgelse til evaluering af effektiviteten og sikkerheden af ​​CIN-102 (Deudomperidon) hos voksne forsøgspersoner med diabetisk gastroparese

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients.

The main questions it aims to answer are:

  • To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with diabetic gastroparesis compared to a placebo
  • To evaluate the safety and tolerability of CIN-102 when given to patients with diabetic gastroparesis compared to a placebo

Participants will go through the following schedule:

  • Screening period (1-2 visits)

  • Lead-in period (1 visit)

    • Will complete a Gastric Emptying Breath Test (GEBT)
    • Will complete daily diary and other Patient Reported Outcomes (PROs) as described in the protocol to assess eligibility for continued study participation
  • 12-week treatment period (7 visits)

    • Study drug taken twice daily by mouth
    • Will complete daily diaries and other PROs as described in protocol
  • 1 week follow-up (1 visit)

Researchers will compare the effects of the following treatments:

  • Drug- CIN-102 Dose 15 mg or 10 mg
  • Drug- Placebo

Studieoversigt

Status

Afsluttet

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

382

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Alabama
      • Dothan, Alabama, Forenede Stater, 36305
        • Digestive Health Specialists of the Southeast
      • Foley, Alabama, Forenede Stater, 36535
        • G & L Research, LLC
      • Huntsville, Alabama, Forenede Stater, 35801
        • Clinical Research Associates, LLC
    • Arizona
      • Peoria, Arizona, Forenede Stater, 85381
        • Phoenix Medical Research Institute, LLC
      • Phoenix, Arizona, Forenede Stater, 85381
        • Onyx Clinical Research
      • Tucson, Arizona, Forenede Stater, 85715
        • Del Sol Research Management, LLC
    • Arkansas
      • Little Rock, Arkansas, Forenede Stater, 72211
        • Preferred Research Partners, Inc.
      • Little Rock, Arkansas, Forenede Stater, 72212
        • Applied Research Center of Arkansas
      • North Little Rock, Arkansas, Forenede Stater, 72117
        • Arkansas Gastroenterology - North Little Rock
    • California
      • Bell Gardens, California, Forenede Stater, 90201
        • Alliance Research Institute - Bell Gardens
      • Canoga Park, California, Forenede Stater, 91303
        • Hope Clinical Research LLC
      • Canoga Park, California, Forenede Stater, 91304
        • Alliance Research Institute, LLC
      • Chula Vista, California, Forenede Stater, 91910
        • GW Research Inc.
      • Chula Vista, California, Forenede Stater, 91910
        • Erick H. Alayo Medical Corporation
      • Corona, California, Forenede Stater, 92879
        • Kindred Medical Institute for Clinical Trials, LLC
      • Corona, California, Forenede Stater, 92882
        • New Hope Research Development
      • Costa Mesa, California, Forenede Stater, 92627
        • Aurora Care Clinic
      • Garden Grove, California, Forenede Stater, 92840
        • Paragon Rx Clinical
      • Garden Grove, California, Forenede Stater, 92845
        • Valley View Wellness and Medical Center - VVCRD
      • Lomita, California, Forenede Stater, 09717
        • Torrance Clinical Research Institute Inc.
      • Los Angeles, California, Forenede Stater, 90010
        • Angel City Research
      • Mission Hills, California, Forenede Stater, 11333
        • Facey Medical Research
      • Thousand Oaks, California, Forenede Stater, 91360
        • Millennium Clinical Trials
    • Florida
      • Clearwater, Florida, Forenede Stater, 33756
        • Innovative Research of West Florida
      • Doral, Florida, Forenede Stater, 33126
        • USA and International Research Inc.
      • Hollywood, Florida, Forenede Stater, 33021
        • Advanced Medical Research Group
      • Inverness, Florida, Forenede Stater, 34452
        • Nature Coast Clinical Research
      • Maitland, Florida, Forenede Stater, 32751
        • ClinCloud LLC
      • Miami, Florida, Forenede Stater, 33144
        • A+ Research Inc
      • Miami, Florida, Forenede Stater, 33183
        • International Research Associates LLC - Breton
      • New Port Richey, Florida, Forenede Stater, 34653
        • Advanced Research Institute Inc
      • Orange City, Florida, Forenede Stater, 32763
        • Gastroenterology of Greater Orlando
      • Viera, Florida, Forenede Stater, 32940
        • Tandem Clinical Research - Viera
    • Georgia
      • Athens, Georgia, Forenede Stater, 30607
        • Summit Clinical Research, LLC
      • Decatur, Georgia, Forenede Stater, 30033
        • Atlanta Center for Gastroenterology P.C.
    • Indiana
      • Evansville, Indiana, Forenede Stater, 47714
        • Medisphere Medical Research Center
      • Fort Wayne, Indiana, Forenede Stater, 46804
        • Lutheran Medical Group
    • Kansas
      • Kansas City, Kansas, Forenede Stater, 66160
        • University of Kansas Medical Center (KUMC)
      • Overland Park, Kansas, Forenede Stater, 66209
        • DelRicht Clinical Research - Overland Park
      • Topeka, Kansas, Forenede Stater, 66606
        • Kansas Medical Clinic, P.A.
      • Wichita, Kansas, Forenede Stater, 67205
        • Alliance for Multispecialty Research - Wichita West
    • Kentucky
      • Louisville, Kentucky, Forenede Stater, 40202
        • University of Louisville
      • Louisville, Kentucky, Forenede Stater, 40205
        • DelRicht Clinical Research - Louisville
    • Louisiana
      • Bastrop, Louisiana, Forenede Stater, 71201
        • Delta Research Partners
      • Houma, Louisiana, Forenede Stater, 70363
        • Tandem Clinical Research GI - Houma
      • Marrero, Louisiana, Forenede Stater, 70072
        • Tandem Clinical Research
      • Metairie, Louisiana, Forenede Stater, 70006
        • Tandem Clinical Research GI - Metairie
    • Michigan
      • Chesterfield, Michigan, Forenede Stater, 48047
        • Clinical Research Institute of Michigan, LLC
      • Flint, Michigan, Forenede Stater, 48504
        • Aa Mrc, Llc
      • Troy, Michigan, Forenede Stater, 48098
        • Clinical Research Institute of Michigan, LLC - Troy
      • Wyoming, Michigan, Forenede Stater, 49519
        • Gastroenterology Associates of Western Michigan
    • Missouri
      • Kansas City, Missouri, Forenede Stater, 64131
        • Kansas City Research Institute
      • St Louis, Missouri, Forenede Stater, 63110
        • Washington University School of Medicine
      • Weldon Spring, Missouri, Forenede Stater, 63304
        • St. Charles Clinical Research
    • Montana
      • Missoula, Montana, Forenede Stater, 59808
        • Montana Medical Research, Inc.
    • Nevada
      • Las Vegas, Nevada, Forenede Stater, 89128
        • Digestive Disease Specialists
      • Las Vegas, Nevada, Forenede Stater, 89123
        • American Institute of Medical Research
    • New Jersey
      • Englewood, New Jersey, Forenede Stater, 07631
        • Allied Health Clinical Research Organization, LLC (AHCRO) - Englewood
      • Freehold, New Jersey, Forenede Stater, 07728
        • Allied Health Clinical Research Organization, LLC (AHCRO) - Freehold
      • Jackson, New Jersey, Forenede Stater, 08527
        • Allied Health Clinical Research Organization, LLC (AHCRO) - Jackson
    • New York
      • Brooklyn, New York, Forenede Stater, 11235
        • NY Scientific
      • Brooklyn, New York, Forenede Stater, 11372
        • Smart Medical Research
      • East Syracuse, New York, Forenede Stater, 13057
        • Velocity Clinical Research - Syracuse
      • New York, New York, Forenede Stater, 10033
        • Tandem Clinical Research GI- New York
      • Richmond Hill, New York, Forenede Stater, 11418
        • A1 Clinical Network
    • North Carolina
      • Charlotte, North Carolina, Forenede Stater, 28144
        • OnSite Clinical Solutions, LLC
      • Charlotte, North Carolina, Forenede Stater, 28204
        • Atrium Health - Center for Digestive Health
      • Denver, North Carolina, Forenede Stater, 28037
        • Research Carolina Elite, LLC
      • Fayetteville, North Carolina, Forenede Stater, 28304
        • Coastal Research Institute, LLC
      • Fayetteville, North Carolina, Forenede Stater, 28304
        • Cross Creek Medical, PA
      • Greensboro, North Carolina, Forenede Stater, 27410
        • Triad Clinical Trials LLC
      • High Point, North Carolina, Forenede Stater, 27260
        • Peters Medical Research
      • Raleigh, North Carolina, Forenede Stater, 27612
        • Carolina's GI Research
    • Ohio
      • Cleveland, Ohio, Forenede Stater, 44195
        • Cleveland Clinic
      • Columbus, Ohio, Forenede Stater, 43215
        • Remington Davis, Inc.
      • Mason, Ohio, Forenede Stater, 45040
        • DelRicht Clinical Research - Cincinnati
      • Westlake, Ohio, Forenede Stater, 44145
        • Northshore Gastroenterology Research, LLC
    • Oklahoma
      • Tulsa, Oklahoma, Forenede Stater, 74104
        • Options Health Research
    • Oregon
      • Medford, Oregon, Forenede Stater, 97504
        • Velocity Clinical Research
    • Pennsylvania
      • Harrisburg, Pennsylvania, Forenede Stater, 17110
        • Susquehanna Research Group, LLC
    • Tennessee
      • Chattanooga, Tennessee, Forenede Stater, 37343
        • Galen Medical Group - Downtown Gastroenterology Location
      • Chattanooga, Tennessee, Forenede Stater, 37421
        • WR ClinSearch
      • Henderson, Tennessee, Forenede Stater, 37075
        • DelRicht Clinical Research - Nashville
    • Texas
      • Arlington, Texas, Forenede Stater, 76012
        • North Hills Medical Research Inc. (North Hills Familiy Medicine)
      • Dallas, Texas, Forenede Stater, 75230
        • Zenos Clinical Research
      • El Paso, Texas, Forenede Stater, 10908
        • Texas Gastro Research, LLC
      • Houston, Texas, Forenede Stater, 77030
        • Houston Methodist Research Institute
      • Houston, Texas, Forenede Stater, 77099
        • Pioneer Research Solutions Inc.
      • Houston, Texas, Forenede Stater, 77089
        • Amir A Hassan, MD, PA
      • Houston, Texas, Forenede Stater, 77090
        • Care and Cure Clinic
      • Lewisville, Texas, Forenede Stater, 75057
        • Epic Clinical Research
      • Lubbock, Texas, Forenede Stater, 79905
        • Texas Tech University Health Sciences Center
      • McAllen, Texas, Forenede Stater, 78503
        • Biopharma Informatic, LLC
      • McKinney, Texas, Forenede Stater, 75070
        • DelRicht Clinical Research - McKinney
      • San Antonio, Texas, Forenede Stater, 78229
        • Gastroenterology Research of San Antonio
      • Spring, Texas, Forenede Stater, 77386
        • A1 Clinical Network
    • Utah
      • Bountiful, Utah, Forenede Stater, 84010
        • HP Clinical Research (Val R. Hansen)
      • West Jordan, Utah, Forenede Stater, 84065
        • Velocity Clinical Research - Salt Lake City
    • Virginia
      • Manassas, Virginia, Forenede Stater, 20110
        • Manassas Clinical Research Center
    • Wisconsin
      • Milwaukee, Wisconsin, Forenede Stater, 53215
        • Wisconsin Center for Advanced Research

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Key Inclusion Criteria:

  • Is a male or female ≥18 years of age;

  • Has a diagnosis of Type 1 or Type 2 diabetes, according to the American Diabetes Association criteria;

  • Has a current diagnosis of diabetic gastroparesis defined by the following:

    1. Persistent gastrointestinal symptoms that in the opinion of the Investigator are consistent with gastroparesis within 6 months prior to Screening; AND
    2. Documented delayed gastric emptying as determined by gastric emptying breath test (GEBT), scintigraphy, or manometry.
  • Body mass index (BMI) between 18 and 49 kg/m2, inclusive;

  • Glycosylated hemoglobin (HbA1c) level <10% at Screening;

  • If receiving treatment with GLP-1RA, may be considered for the study if all of the following criteria are satisfied:

    1. The GLP-1 RA has been prescribed for the management of diabetes and not specifically for weight loss/weight management;
    2. Has been on a stable dose of GLP-1RA for a minimum of 3 months before Screening and is anticipated to sustain the same dose during GEBT and throughout the study;
    3. Is tolerating the GLP-1RA well based on Investigator's judgment;
    4. None of the study-qualifying signs/symptoms of gastroparesis are solely attributable to the use of GLP-1RA; and
    5. The symptoms of gastroparesis preceded the initiation of GLP-1RA therapy.
  • Willing to washout from ongoing treatment for gastroparesis.

Key Exclusion Criteria:

  • Has known cause of gastroparesis other than diabetes (eg, idiopathic gastroparesis and/or gastroparesis attributed to surgery, viral illness, cancer, scleroderma, or other neurologic disorder);
  • Has been hospitalized within 3 months prior to Visit 1 for diabetic gastroparesis and/or diabetic ketoacidosis and/or malnutrition;
  • History or evidence of clinically significant arrhythmia;
  • History of pyloroplasty, pyloromyotomy, or gastric peroral endoscopic myotomy, fundoplication, gastrectomy, vagotomy, or bariatric surgery;
  • Currently receiving parenteral feeding or presence of a nasogastric or other enteral tube for feeding or decompression;
  • Pyloric injection of botulinum toxin within 6 months of Screening;
  • Positive test for drugs of abuse;
  • Has a known allergy to eggs or spirulina;
  • Females who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: CIN-102: Dose 15mg or 10mg

CIN-102, Dose 15 mg or 10 mg, twice daily for 12 weeks

2 capsules twice daily for 12 weeks

Placebo komparator: Placebo

Placebo for CIN-102, twice daily for 12 weeks

2 capsules twice daily for 12 weeks

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Effect of CIN-102 to significantly decrease gastroparesis-related symptoms as compared to baseline based on the composite of the average ANMS GCSI-DD Nausea Sub-Scale and Vomiting Scores
Tidsramme: Over the last 2 weeks of the 12-week Treatment Period as compared to baseline

The American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) Nausea Subscale scores and the Vomiting subscale scores will be averaged into a single value that ranges 0-4 (0 for no symptom and 4 for very severe)

Over the last 2 weeks of the 12-week Treatment Period as compared to baseline

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Forekomst af klinisk signifikante ændringer, efter Investigators opfattelse, i laboratorieparametre, fysiske undersøgelsesfund, 12-aflednings EKG-parametre, vægtmåling.
Tidsramme: Over den 12-ugers behandlingsperiode
Over den 12-ugers behandlingsperiode
Forekomst af behandlingsfremkaldte bivirkninger (TEAE'er)
Tidsramme: Over den 12-ugers behandlingsperiode
Over den 12-ugers behandlingsperiode
Forekomst af alvorlige bivirkninger (SAE'er)
Tidsramme: Over den 12-ugers behandlingsperiode
Over den 12-ugers behandlingsperiode
Forekomst af TEAE'er, der fører til for tidlig seponering af studielægemidlet
Tidsramme: Over den 12-ugers behandlingsperiode
Over den 12-ugers behandlingsperiode
Forekomst af behandlingsfremkaldte markante laboratorieabnormiteter.
Tidsramme: Over den 12-ugers behandlingsperiode
Over den 12-ugers behandlingsperiode
Alle endepunkter, der evalueres i løbet af de sidste 2 uger af den 12-ugers behandlingsperiode, vil også blive evalueret i løbet af de sidste 6 uger af den 12-ugers behandlingsperiode.
Tidsramme: I løbet af de sidste 6 uger af den 12-ugers behandlingsperiode
I løbet af de sidste 6 uger af den 12-ugers behandlingsperiode
Ændring i PGIS med hver dosis af CIN-102
Tidsramme: Fra baseline til uge 12
Fra baseline til uge 12
Ændring i PGIC med hver dosis af CIN-102
Tidsramme: Fra baseline til uge 12
Fra baseline til uge 12
Procentdel af respondere, der viser en gennemsnitlig ≥0,5 reduktion fra baseline på ANMS GCSI-DD Kvalme-underskalaen og opkastningsresultater
Tidsramme: I løbet af de sidste 2 uger af den 12-ugers behandlingsperiode
I løbet af de sidste 2 uger af den 12-ugers behandlingsperiode
Procentdel af forsøgspersoner, der opnår en ≥30 % reduktion fra baseline på en sammensætning af den gennemsnitlige ANMS GCSI-DD Kvalme-underskala og opkastningsresultater
Tidsramme: I løbet af de sidste 2 uger af den 12-ugers behandlingsperiode
I løbet af de sidste 2 uger af den 12-ugers behandlingsperiode
Forholdet mellem ANMS GCSI-DD Nausea Sub-Scale og opkastningsscore og Patient Global Impression of Severity (PGIS) og Patient Global Impression of Change (PGIC) over den 12-ugers behandlingsperiode;
Tidsramme: Over den 12-ugers behandlingsperiode
Over den 12-ugers behandlingsperiode
Ændringen i sammensætningen af ​​den gennemsnitlige ANMS GCSI-DD Kvalme-underskala og opkastningsscore blandt forsøgspersoner, der modtager glukagon-lignende peptid-1-receptoragonist (GLP-1RA)
Tidsramme: Over den 12-ugers behandlingsperiode sammenlignet med baseline
Over den 12-ugers behandlingsperiode sammenlignet med baseline
Procentdelen af ​​respondere blandt forsøgspersoner, der modtog GLP-1RA, som viser en gennemsnitlig ≥0,5 reduktion fra baseline på ANMS GCSI-DD Nausea Sub-Scale og opkastningsresultater
Tidsramme: I løbet af de sidste 2 uger af den 12-ugers behandlingsperiode
I løbet af de sidste 2 uger af den 12-ugers behandlingsperiode
Procentdelen af ​​forsøgspersoner, der modtager GLP-1RA, som opnår en reduktion på ≥30 % fra baseline på ANMS GCSI-DD Kvalme-underskalaen og opkastningsresultaterne
Tidsramme: I løbet af de sidste 2 uger af den 12-ugers behandlingsperiode
I løbet af de sidste 2 uger af den 12-ugers behandlingsperiode
Ændringen i ANMS GSCI-DD Total Score og en sammensætning af gastroparese-relaterede symptomer blandt forsøgspersoner, der modtager GLP-1RA;
Tidsramme: over de sidste 2 uger af den 12-ugers behandlingsperiode sammenlignet med baseline
over de sidste 2 uger af den 12-ugers behandlingsperiode sammenlignet med baseline
The percentage of symptom-free days in the ANMS GCSI-DD Total Score, a composite of the Nausea Sub-Scale and Vomiting Scores, and Sub-Scale Scores
Tidsramme: Over the last 2 weeks of the 12-week Treatment Period

Symptomatic days defined as >mild (ANMS GCSI-DD scores >2)

Over the last 2 weeks of the 12-week Treatment Period
Percentage of subjects with a history of a lack of response or who could not tolerate metoclopramide therapy or other prokinetics, who demonstrate a >30% reduction from baseline on a composite score
Tidsramme: Over the last 2 weeks of the 12-week Treatment Period as compared to baseline

Composite of the average ANMS GCSI-DD Nausea Sub-Scale and Vomiting Scores

Over the last 2 weeks of the 12-week Treatment Period as compared to baseline
Effect of CIN-102 to significantly decrease the severity of gastroparesis-related symptoms as compared to baseline
Tidsramme: Over the last 2 weeks of the 12-week Treatment Period as compared to baseline

Based on the average ANMS GCSI-DD Total and Sub-Scale Scores

Over the last 2 weeks of the 12-week Treatment Period as compared to baseline

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

27. marts 2023

Primær færdiggørelse (Faktiske)

14. november 2025

Studieafslutning (Faktiske)

12. december 2025

Datoer for studieregistrering

Først indsendt

16. marts 2023

Først indsendt, der opfyldte QC-kriterier

14. april 2023

Først opslået (Faktiske)

27. april 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner